Research Analysts Issue Forecasts for InflaRx Q3 Earnings

InflaRx N.V. (NASDAQ:IFRX) – Research analysts at HC Wainwright issued their Q3 2026 earnings estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller forecasts that the company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at ($0.52) EPS.

IFRX has been the subject of a number of other reports. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Finally, Guggenheim reduced their target price on shares of InflaRx from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, March 20th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.17.

InflaRx Stock Performance

Shares of NASDAQ:IFRX opened at $1.02 on Monday. The business’s fifty day moving average price is $0.92 and its two-hundred day moving average price is $1.13. The stock has a market cap of $73.74 million, a PE ratio of -1.34 and a beta of 1.48. InflaRx has a one year low of $0.71 and a one year high of $1.94.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of ($0.04) million for the quarter, compared to analyst estimates of $0.03 million.

Hedge Funds Weigh In On InflaRx

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of InflaRx in the 4th quarter valued at about $135,000. Suvretta Capital Management LLC increased its position in InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after purchasing an additional 1,450,000 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in InflaRx during the 4th quarter worth approximately $104,000. Eversept Partners LP raised its holdings in InflaRx by 1.5% in the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock valued at $1,775,000 after buying an additional 26,677 shares during the period. Finally, 683 Capital Management LLC raised its holdings in InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after buying an additional 1,065,000 shares during the period. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.